Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

Sponsor
The First Affiliated Hospital of Zhengzhou University
Study ID
NCT03387904
Phase
PHASE2
Status
Unknown

Conditions

  • Esophageal Squamous Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

To compare the effects and safety of Anlotinib Plus Irinotecan versus Irinotecan in patients with esophageal squamous cell carcinoma(ESCC).

Key Dates

Start date
Jan 13, 2019
Status verified
Aug 2021
Primary completion
Dec 1, 2021
Completion
Dec 1, 2022

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Anlotinib Plus Irinotecan
    Anlotinib QD po.and Irinotecan Day 1,8 ivgtt. Both should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
  • Active Comparator: Irinotecan
    Irinotecan Day 1,8 ivgtt and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

Primary Outcome Measure

Progress free survival (PFS) [ Time Frame: up to 24 months ]

Central Contacts

Related Studies